Serum tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) and IL-17 levels are associated with disease activity in systemic lupus erythematosus patients with and without nephritis
Open Access
- 18 April 2019
- journal article
- research article
- Published by Maad Rayan Publishing Company in Journal of Renal Injury Prevention
- Vol. 8 (3) , 204-210
Abstract
Introduction: Lupus nephritis (LN) is one of the most severe signs of systemic lupus erythematosus (SLE) and rapid diagnosis of kidney damage remains an important concern for LN. Objectives: The aim of this study was to investigate the association of the serum levels of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and interleukin 17 (IL-17) with SLE severity, renal involvement, and other clinical manifestations in lupus patients. Patients and Methods: In order to determine a better biomarker for the detection of renal damage, this study evaluated the ability of serum TWEAK (sTWEAK) and IL-17 in lupus patients with (n=25) and without (n=25) nephritis and healthy controls (n=39). Moreover, it compared the levels of these cytokines with disease activity and chronicity as well as traditional serum markers including complement C3 and C4, creatinine, and proteinuria in lupus patients. Results: Increased levels of sTWEAK and IL-17 were observed in SLE and LN groups compared to healthy controls and non-LN groups, respectively. Significant positive associations were observed between serum TWEAK and IL-17 levels and systemic lupus erythematosus disease activity index (SLEDAI), proteinuria, nephritis activity index, and some clinical manifestations (PConclusion: The serum levels of TWEAK and IL-17 in the SLE and LN groups were significantly higher than the control group and both markers were indicative of the renal disease severity; therefore, they could possibly indicate renal involvement in the lupus patients.Keywords
This publication has 25 references indexed in Scilit:
- Assessment of urinary TWEAK levels in Mexican patients with untreated lupus nephritis: An exploratory studyNefrología, 2018
- Lupus nephritis biomarkersClinical Immunology, 2017
- The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritisCytokine, 2015
- Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activityCytokine, 2015
- IL-17 cytokines in immunity and inflammationEmerging Microbes & Infections, 2013
- Role of TWEAK in lupus nephritis: A bench-to-bedside reviewJournal of Autoimmunity, 2012
- The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritisNephrology Dialysis Transplantation, 2011
- Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: Implications for Th17-mediated inflammation in auto-immunityClinical Immunology, 2008
- Urinary TWEAK and the activity of lupus nephritisJournal of Autoimmunity, 2006
- TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptorCytokine & Growth Factor Reviews, 2003